Business
IXICO Updates AI Neuroimaging Platform
IXICO plc has released version 10 of its AI-driven neuroimaging platform, IXI™, which enhances data processing speed and volume, improves image reading precision, and integrates new tools for remote access and data quality. This latest generation of IXI™ supports IXICO's TechBio strategy by enabling external organizations to access the technology through licensing and partnering models, aiming to expand the company's addressable market and assist biopharmaceutical companies in making earlier, more informed decisions in drug development for neurological disorders. Disclaimer*
About this update from Ixico Plc
[{"type":"text","content":"\n\nIXICO plc\n(\"IXICO\", the \"Company\" or the \"Group\")\n \nIXICO RELEASES LATEST VERSION OF AI-DRIVEN NEUROIMAGING TECHNOLOGY PLATFORM\n \nIXI™ (Version 10) advances data processing speed and volume\n \n \n12 May 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in neuroscience imaging and biomarker analytics, using its AI-driven platform to help advance drug development in neurological disorders, today announced the latest version release (v.10) of IXI™, IXICO's proprietary AI enabled neuroimaging platform that delivers clinical trial imaging and biomarker insights in neurological disease research.\n \nThe IXI™ 10.0 release brings advances in image reading precision and analysis, enables larger and faster image data processing, and integrates new tools for remote image access and data quality qualification. The latest generation of IXI™ lays the foundation for IXICO's technology to move beyond its traditional iCRO remit as part of the Group's TechBio strategy. The strategy is focused on increasing IXICO's addressable market by enabling external organisations to directly access IXICO's technology via licensing, technology integration and partnering models such as the recently announced collaboration with Medidata (26 March 2026). \n \nAbout IXI™\nDesigned by neuroscience and data science experts, the IXI™ Platform is a proprietary suit of technologies and AI tools tailor-made for neurological disease complexity. IXI™ uses machine learning and deep learning to reliably process data from global trials and build algorithms that precisely measure key imaging biomarkers associated with the identification, progression and treatment of Alzheimer's, Parkinson's, Huntington's and other rare neurological diseases. It is the only technology platform of its kind specifically built for, and exclusively focussed on, neuroimaging processing and neurological biomarker analysis. \n \nIXI™ is being used every day across the world. With over 30 cutting edge analytics algorithms the Platform integrates standardised high quality image data capture, image reading, advanced analysis and regulatorily compliant reporting of clinical data. IXI™ supports the biopharma industry to develop new medicines and diagnostic measures, informing decisions earlier in the dr...